Inhibition by new glucocorticoid antedrugs [16α, 17α-d] isoxazoline and [16α, 17α-d]-3′-hydroxy-iminoformyl isoxazoline derivatives of chemotaxis and CCL26, CCL11, IL-8, and RANTES secretion

Journal of Interferon and Cytokine Research

Volumn 33, Issue 9, 2013, Pages 493-507

  Errahali, Younes J ^a   Thomas, Leeshawn D ^a   Keller III, Thomas C S ^b   Lee, Henry J ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

^b FLORIDA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EOTAXIN; EOTAXIN 3; INTERLEUKIN 8; ISOXAZOLINE DERIVATIVE; OXIME DERIVATIVE; PREDNISOLONE; RANTES;

ARTICLE; ASTHMA; CELL ACTIVATION; CELL PROLIFERATION; CHRONIC RESPIRATORY TRACT DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; EOSINOPHIL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN SECRETION; RESPIRATORY EPITHELIUM; TH1 CELL; TH2 CELL;

ANTI-INFLAMMATORY AGENTS; APOPTOSIS; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CHEMOKINE CCL11; CHEMOKINE CCL5; CHEMOKINES, CC; CHEMOTAXIS, LEUKOCYTE; EOSINOPHILS; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; INTERLEUKIN-8; PNEUMOCYTES;

EID: 84883697781     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2012.0129     Document Type: Article

References (79)

1. Adcock JC, Ito K. 2000. Molecular mechanisms of corticosteroid actions. Monaldi Arch Chest Dis 55:256-266.
2. Adelroth E, Rosenhall L, Johansson SA, Linden M, Venge P. 1990. Inflammatory cells and eosinophilic activity in asthmatics investigated by bronchoalveolar lavage. The effects of antiasthmatic treatment with budesonide or terbutaline. Am Rev Respir Dis 142:91-99.
3. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. 2006. Inflammation and cancer: how hot is the link? Biochem Pharmacol 72:1605-1621.
4. Alekseev EI, Sshakhbazian IE, Ulybina OV, Khudoleeva EI. 2001. Effectiveness and side-effects of long-term treatment with glucocorticoids in patients with juvenile rheumatoid arthritis. Klin Med 79:33-38.
5. Amano Y, Lee SW, Alison AC. 1993. Inhibition by glucocorticoids of the formation of interleukin-1 alpha, interleukin-1 beta and interleukin-6: mediation by decreased mRNA stability. Mol Pharmacol 43:176-182.
6. Bacon K, Baggiolini M, Broxmeyer H, Horuk R, Lindley I, Mantovani A, Maysushima K, Wadhwa M, Yoshie O, Zlotnik A, Zook K. 2002. IUIS/WHO subcommittee on chemokines nomenclature. Chemokine/chemokine receptor nomenclature. J Interferon Cytokine Res 22:1067-1068.
7. Barnes PJ. 1995. Inhaled glucocorticoids for asthma. N Engl J Med 332:868-875.
8. Barnes PJ. 1996. Molecular mechanisms of steroid action in asthma. J Allergy Clin Immunol 97:159-168.
9. Barnes PJ, Chung KF, Page CP. 1998a. Inflammatory mediators of asthma: an update. Pharmacol Rev 50:515-596.
10. Barnes PJ, Pedersen S, Busse WW. 1998b. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 157:S1-S53.
11. Bazzoni F, Cassatella MA, Rossi F, Ceska M, Dewald B, Baggiolini M. 1991. Phagocytosing neutrophils produce and release high amounts of the neutrophil-activating peptide 1/interleukin 8. J Exp Med 173:771-774.
12. Berkman N, Krishnan VL, Gilbey T, et al. 1996. Expression of RANTES mRNA and protein in airways of patients with mild asthma. Am J Respir Crit Care Med 154:1804-1811.
13. Bodor N. 2000. Recent advances in retrometabolic drug design and targeting approaches. Pharmazie 55:163-166.
14. Burke C, Power CK, Norris A, Condez A, Schmekel B, Poulter LW. 1992. Lung function and immunopathological changes after inhaled corticosteroid therapy in asthma. Eur Respir J 5:73-79.
15. Charo IF, Ransohoff RM. 2006. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006;354:610-621.
16. Collins PD, Weg VB, Faccioli LH, Watson ML, Moqbel R, Williams TJ. 1993. Eosinophil accumulation induced by human interleukin-8 in the guinea-pig in vivo. Immunology 79:312-318.
17. Del Pozo V, De Andrés B, Mart?́n E, Cárdaba B, Fernández JC, Gallardo S, Tramón P, Leyva-Cobian F, Palomino P, Lahoz C. 1992. Eosinophil as antigen-presenting cell: activation of T cell clones and T cell hybridoma by eosinophils after antigen processing. Eur J Immunol 22:1919-1925.
18. Djukanović R, Wilson JW, Britten KM, Wilson SJ, Walls AF, Roche WR, Howarth PH, Holgate ST. 1992. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 145:669-674.
19. Encio IJ, Detera-Wadleigh SD. 1991. The genomic structure of the human glucocorticoid receptor. J Biol Chem 266:7182-7188.
20. Errahali YJ, Taka E, Abonyo BO, Heiman AS. 2009. CCL26-targeted siRNA treatment of alveolar type II cells decreases expression of CCR3-binding chemokines and reduces eosinophil migration: implications in asthma therapy. J Interferon Cytokine Res 29:227-239.
21. Fan J, Heller NM, Gorospe M, Atasoy U, Stellato C. 2005. The role of post-transcriptional regulation in chemokine gene expression in inflammation and allergy. Eur Respir J 26:933-947.
22. Foresi A, Bertorelli G, Pesci A, Chetta A, Olivieri D. 1990. Inflammatory markers in bronchoalveolar lavage and in bronchial biopsy in asthma during remission. Chest 98:528-535.
23. Ganzalo JA, Jia GQ, Aguirre V, Friend D, Coyle AJ, Jenkins NA, Lin GS, Katz H, Lichtman A, Copeland N, Kopf M, Gutierrez-Ramos JC. 1996. Mouse Eotaxin expression parallels eosinophil accumulation during lung allergic inflammation but it is not restricted to a Th2-type response. Immunity 4:1-14.
24. Garcia G, Godot V, Humbert M. 2005. New chemokine targets for asthma therapy. Curr Allergy asthma Rep 5:155-160.
25. Garcia-Zepeda EA, Rothenberg ME, Owenbey RT, Celestin J, Leder P, Luster AD. 1996. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med 2:449-456.
26. Green RH, Brighting CE, Mckenna S, Hargadon B, Parker D, Bradding P, Wardlaw AJ, Pavord ID. 2002. Asthma exacerbations and sputum eosinophil counts: a randomized controlled trial. Lancet 360:1715-1721.
27. Griffiths-Johnson DA, Collins PD, Rossi AG, Jose PJ, Williams TJ. 1993. The chemokine, eotaxin, activates guinea-pig eosinophils in vitro and causes their accumulation into the lung in vivo. Biochem Biophys Res Commun 197:1167-1172.
28. Hansel TT, De Vries IJ, Carballido JM, Braun RK, Carballido-Perrig N, Rihs S, Blaser K, Walker C. 1992. Induction and function of eosinophil intercellular adhesion molecule-1 and HLA-DR. J Immunol 149:2130-2136.
29. Holgate ST. 2007. Epithelium dysfunction in asthma. J Allergy Clin Immunol 120:1233-1244.
30. Hwang SK, Juhasz A, Yoon SH, Bodor N. 2000. Design, synthesis and evaluation of soft bufuralol analogues. J Med Chem 43:1525-1532.
31. Jamieson CAM, Yamamoto KR. 2000. Crosstalk pathway for inhibition of glucocorticoid-induced apoptosis by T cell receptor signaling. Proc Natl Acad Sci USA 97:7319-7324.
32. Ji F, Huang F, Juhasz A, Wu W, Bodor N. 2000. Design, synthesis and evaluation of soft glycopyrrolate and its analog. Pharmazie 55:187-191.
33. Jose PJ, Griffiths-Johnson DA, Collins PD, Walsh DT, Moqbel R, Totty NF, Truong O, Hsuan JJ, Williams TJ. 1994. Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. J Exp Med 179:881-887.
34. Kern JA, Lamb RJ, Reed JC, Daniele RP, Nowell PC. 1988. Dexamethasone inhibition of interleukin 1 beta production by human monocytes. Post-transcription mechanisms. J Clin Invest 81:237-244.
35. Khalil MA, Maponya MG, Ko DH, You Z, Oriaku ET, Lee HJ. 1996. New anti-inflammatory steroids: [16a,17 a-d] isoxazolinederivatives of prednisolone and 9 a-fluoroprednisolone. Med Chem Res 6:52-60.
36. Khan MOF, Park KK, Lee HJ. 2005. Antedrugs: an approach to safer drugs. Curr Med Chem 12:2227-2239.
37. Kimura T. 1994. Antedrugs and pro-antedrugs of corticosteroids. Jpn J Clin Med 52:691-697.
38. Ko DH, Maponya MG, Khalil MA, Oriaku ET, You Z, Lee HJ. 1997. New anti-inflammatory steroids: [16 a,17 a-d]-3¢-hydroxy-iminoformyl isoxazoline derivatives of prednisolone and 9a-fluoroprednisolone. Med Chem Res 7:313-324.
39. Kraft M, Djukanovic R, Torvik J, Cunningham L, Henson J, Wilson S, Holgate ST, Hyde D, Martin R. 1995. Evaluation of airway inflammation by endobronchial and transbronchial biopsy in nocturnal and nonnocturnal asthma. Chest 107:162S.
40. Kwon T, Heiman AS, Oriaku ET, Yoon K, Lee HJ. 1995. New steroidal anti-inflammatory antedrugs: steroidal [16 a,17 a-d]-3¢- carbethoxyisoxazolines. J Med Chem 38:1048-1051.
41. Laitinen LA, Laitinen A, Haahtela T. 1992. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallelgroup controlled trial. J Allergy Clin Immunol 90:32-42.
42. Lee HJ, Ko DH. 1999. A novel approach to the discovery of nonsystemic anti-inflammatory steroids; antedrug. Arch Pharm Res 22:279-287.
43. Lee HJ, Soliman MRI. 1982. Anti-inflammatory steroids without pituitary adrenal suppression. Science 215:989-991.
44. Lilly CM, Nakamura H, Kesselman H, Nagler-Anderson C, Asano K, Garcia-Zepeda EA, Rothenberg ME, Drazen JM, Luster AD. 1997. Expression of eotaxin by human lung epithelial cells: induction by cytokines and inhibition by glucocorticoids. J Clin Invest 99:1767-1773.
45. Little RJ, Bodor N, Loftsson T. 1999. Soft drugs based on hydrocortisone: the inactive metabolite approach and its application to steroidal anti-inflammatory agents. Pharm Res 16:961-967.
46. Lloyd C. 2002. Chemokines in allergic lung inflammation. Immunology 105:144-154.
47. Masi AT, Chrousos GP. 1996. Hypothalamic-pituitary-adrenalglucocorticoid axis function in rheumatoid arthritis. J Rheumatol 23:577-581.
48. McCain RW, Dessypris EN, Christman JW. 1993. Granulocyte/macrophage colony-stimulating factor stimulates human polymorphonuclear leukocytes to produce interleukin-8 in vitro. Am J Respir Cell Mol Biol 8:28-34.
49. Minneci PC, Deans KJ, Banks SM, Eichacker PQ, Natanson C. 2004. Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 141:47-56.
50. Mozo L, Gayo A, Suarez A, Rivas D, Zamorano J, Gutierrez C. 1998. Glucocorticoids inhibit IL-4 and mitogen-induced IL-4R alpha chain expression by different post-transcriptional mechanisms. J Allergy Clin Immunol 102:968-976.
51. Muller M, Renkawitz R. 1991. The glucocorticoid receptor. Biochim Biophys Acta 1088:171-182.
52. Murphy P, Nomiyama H, Oppenheim J, Rot A, Schall T, Tsang M, Thorpe R, van Damme J, Murphy PM. 2002. International Union of Pharmacology. Update on chemokine receptor nomenclature. Pharmacol Rev 54:227-229.
53. Nishimura J, Ikuyama S. 2000. Glucocorticoid-induced osteoporosis: pathogenesis and management. J Bone Miner Metab 18:3350-3352.
54. Park KK, Ko DH, You Z, Khan MO, Lee HJ. 2006. In vitro antiinflammatory activities of new steroidal antedrugs: [16a,17 a-d] Isoxazoline and [16 a,17 a-d]-3¢-hydroxy-iminoformyl isoxazoline derivatives of prednisolone and 9 a-fluoroprednisolone. Steroids 71:183-188.
55. Pease JE, Williams TJ. 2006. Chemokines and their receptors in allergic disease. J Allergy Clin Immunol 118:305-318.
56. Phillips RM, Stubbs VEL, Henson MR, Williams TJ, Pease JE, Sabroe I. 2003. Variations in eosinophil chemokine responses: an investigation of CCR1 and CCR3 function, expression in atopy and identification of a functional CCR1 promoter. J Immunol 170:6190-6201.
57. Ponath PD, Qin S, Ringler DJ, Clark-Lewis I, Wang J, Kassam N, Smith H, Shi X, Gonzalo JA, Newman W, Gutierrez-Ramos JC, Mackay CR. 1996a. Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest 97:604-612.
58. Ponath PD, Qin S, Post TW, Wang J, Wu L, Gerard NP, Newman W, Gerard C, Mackay Cr. 1996b. Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J Exp Med 183:2437-2448.
59. Procopiou PA, Biggadike K, English AF, Farrell RM, Hagger GN, Hancock AP, et al. 2001. Novel glucocorticoid antedrugspossessing a 17b-(g-lactone) ring. J Med Chem 44:602-612.
60. Resnick MB, Weller PF. 1993. Mechanisms of eosinophil recruitment. Am J Respir Cell Mol Biol 8:349-355.
61. Rot A, Krieger M, Brunner T, Bischoff SC, Schall TJ, Dahinden CA. 1992. RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes. J Exp Med 176:1489-1495.
62. Rothenberg ME, Luster AD, Leder P. 1995a. Murine eotaxin: an eosinophil chemoattractant inducible in endothelial cells and in interleukin 4-induced tumor suppression. Proc Natl Acad Sci USA 92:8960-8964.
63. Rothenberg ME, Luster AD, Lilly CM, Drazen JM, Leder P. 1995b. Constitutive and allergen-induced expression of eotaxin mRNA in the guinea pig lung. J Exp Med 181:1211-1216.
64. Rothenberg ME, Ownbey R, Mehlhop PD, Loiselle PM, van de Rijn M, Bonventre JV, Oettgen HC, Leder P, Luster AD. 1996. Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin 5 in mice. Mol Med 2:334-348.
65. Sambrook P, Raj A, Hunter D, Naganathan V, Mason R, Robinson B. 2001. Osteoporosis with low dose corticosteroids: contribution of underlying disease effects and discriminatory ability of ultrasound versus bone densitometry. J Rheumatol 28:1063-1067.
66. Sawa M, Tsukamoto T, Kiyoi T, Kurogawa K, Nakajima F, Nakada Y, et al. 2002. New strategy for antedrug application: development of metalloproteinase inhibitors as antipsoriatic drugs. J Med Chem 45:930-936.
67. Schröder JM, Christophers E. 1989. Secretion of novel and homologous neutrophil-activating peptides by LPS-stimulated human endothelial cells. J Immunol 142:244-251.
68. Schweizer RC, Welmers BA, Raaijmakers JA, Zanen P, Lammers JW, Koenderman L. 1994. RANTES-and interleukin-8-induced responses in normal human eosinophils: effects of priming with interleukin-5. Blood 83:3697-3704.
69. Sehmi R, Cromwell O, Wardlaw AJ, Moqbel R, Kay AB. 1993. Interleukin-8 is a chemo-attractant for eosinophils purified from subjects with a blood eosinophilia but not from normal healthy subjects. Clin Exp Allergy 23:1027-1036.
70. Takahashi GW, Andrews DF 3rd, Lilly MB, Singer JW, Alderson MR. 1993. Effect of granulocyte-macrophage colony-stimulating factor and interleukin-3 on interleukin-8 production by human neutrophils and monocytes. Blood 81:357-364.
71. Villar MTA, Douglass J, Shute J, Church MK, Holgate ST. 1993. Interleukin-8 is a chemoattractant for eosinophils primed with interleukin-4. Am Rev Respir Dis 147:A242.
72. Warringa RA, Mengelers HJ, Raaijmakers JA, Bruijnzeel PL, Koenderman L. 1993. Upregulation of formyl-peptide and interleukin-8-induced eosinophil chemotaxis in patients with allergic asthma. J Allergy Clin Immunol 91:1198-1205.
73. Wei S, Liu JH, Blanchard DK, Djeu JY. 1994. Induction of IL-8 gene expression in human polymorphonuclear neutrophils by recombinant IL-2. J Immunol 152:3630-3636.
74. Weller PF, Rand TH, Barrett T, Elovic A, Wong DT, Finberg RW. 1993. Accessory cell function of human eosinophils. HLA-DRdependent, MHC-restricted antigen-presentation and IL-1 alpha expression. J Immunol 150:2554-2562.
75. Wertheim WA, Kunkel SL, Standiford TJ, Burdick MD, Becker FS, Wilke CA, Gilbert AR, Strieter RM. 1993. Regulation of neutrophil-derived IL-8: the role of prostaglandin E2, dexamethasone, and IL-4. J Immunol 151:2166-2175.
76. Ying S, Meng Q, Zeibecoglou K, et al. 1999. Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (intrinsic) asthmatics. J Immunol 163:6321-6329.
77. You Z, Heiman AS, Hudson CE, Lee HJ. 2002. Effect of chirality at C-20 of methyl 11b,17a,20-trihydroxyl-3-0 • 0-1,4-pregnadien-21-oate derivatives on anti-inflammatory activity. Steroids 67:353-359.
78. Yousefi S, Hemmann S, Weber M, Hö lzer C, Hartung K, Blaser K, Simon HU. 1995. IL-8 is expressed by human peripheral blood eosinophils. Evidence for increased secretion in asthma. J Immunol 154:5481-5490.
79. Zimmermann N, Hershey GK, Foster PS, Rothenberg ME. 2003. Chemokines in asthma: cooperative interactions between chemokines and IL-13. J Allergy Clin Immunol 111:227-242